13.65
+11.75%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vir Biotechnology
From its filings with the US Securities and Exchange Commission
Vir Biotechnology is based in San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VIR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $68.6m and a net loss of $438.0m. At that date it held total assets of $1.00bn and shareholders' equity of $765.3m.
Vir Biotechnology, Inc. (including its subsidiaries, referred to as “Vir Bio,” “the Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.
These diseases represent formidable challenges to human health. Under normal conditions, our immune system is naturally equipped to protect us by identifying and eradicating both cancer cells and viruses. However, these threats have evolved sophisticated mechanisms to evade our immune defenses. When cancer cells or viruses successfully bypass our immune system, they have the potential to cause diseases that may be life-threatening. We are focused on developing therapies that enhance the immune system’s ability to overcome these evasion tactics, effectively powering the immune system to combat viruses and fight cancer.
We believe our unified approach of leveraging our deep understanding of immunology to address seemingly disparate threats distinguishes us in the field. Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.
Quoted from its 10-K, filed 23 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Oct 2019
- Employees
- 367
- Website
- vir.bio ↗
- Head office
- 1800 OWENS STREET, SAN FRANCISCO, CA, 94158
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Vicki SatoIndependent Chairman of the Board$295,583
- Dr. Marianne De BackerPresident, Chief Executive Officer, since 2023$9.3m
- Mr. Jason O'byrneChief Financial Officer, Executive Vice President$1.9m
- Dr. Maninder HoraExecutive Vice President, Chief Technical Operations Officer
- Ms. Vanina De VerneuilExecutive Vice President, General Counsel, Corporate Secretary$1.7m
- Dr. Mark EisnerExecutive Vice President, Chief Medical Officer$2.8m
- Dr. Norbert BischofbergerIndependent Director$445,136
- Dr. Ramy FaridIndependent Director$446,336
- Mr. Jeffrey HatfieldIndependent Director$279,474
- Mr. Robert MoreIndependent Director$283,083
- Ms. Janet NapolitanoIndependent Director$270,583
- Ms. Saira RamasastryIndependent Director$285,926
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 35
- Social
- 99
- Governance
- 37
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vir Biotechnology Inc has several strengths that provide it with a competitive advantage:
Weaknesses
- While Vir Biotechnology Inc enjoys various strengths, it also faces certain weaknesses:
Opportunities
- Vir Biotechnology Inc can capitalize on the following opportunities:
Threats
- There are several potential threats that Vir Biotechnology Inc should consider:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.